CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) and led by Canadian Cancer Trials Group (CCTG), were published in the Journal of Clinical Oncology.
“This trial tested the drug durvalumab, an immune checkpoint inhibitor which helps the body’s immune system recognize and attack cancer cells. These agents do not directly kill cancer cells but instead promote the immune system’s ability to fight and destroy cancer cells,” says the Canadian trial leader Dr Glenwood Goss, Emeritus Professor of Medicine and Senior Clinical Researcher at the Ottawa Hospital Research Institute and University of Ottawa.
Lung cancer, the second most common cancer in North America is the leading cause of death in both men and women and NSCLC accounts for 80-85% of all lung cancer.
The results indicated that adjuvant durvalumab did not significantly improve disease-free survival (DFS) compared with placebo in the primary study population. As a result, the study did not meet its primary endpoint, which was to demonstrate a significant improvement in DFS among patients whose tumours had a tumour cell PD-L1 expression of 25% or greater and were EGFR/ALK wild-type.
Dr Goss further noted that, “There have been two other trials evaluating checkpoint inhibitors in a similar setting which have shown an improvement in disease free survival. Despite their effectiveness in advanced disease, further research is needed to understand the biology and optimize the use of these agents in earlier disease while minimizing toxicity for patients.”
About the trial
The trial investigated the use of the drug durvalumab (Imfinzi) as an adjuvant treatment for patients with completely resected non-small cell lung cancer (NSCLC).
Researchers randomized 1415 patients in a 2:1 design to receive either durvalumab or placebo following completed resection of all cancer and optional adjuvant chemotherapy. The trial was conducted at 269 sites in 19 countries via an international consortium of 10 academic cancer cooperative groups.
CCTG is happy to announce the launch of the new Investigator Leadership Mentoring and Training (VISION) program.
2025 was marked by scientific excellence, operational achievement, and renewed national and international recognition of the Canadian Cancer Trials Group’s leadership in academically driven cancer clinical trials. These accomplishments are a direct result of the extraordinary commitment of our investigators, site teams, patient partners, and staff across the CCTG network.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy long-term analysis was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third sub study IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
The CCTG SR.8 (HARMONY) clinical trial has been awarded almost 1.5 million through the CIHR spring Project Grant Program. A phase III study that addresses a significant unmet need in the treatment of high-risk soft-tissue sarcoma (STS).
We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.
Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems.
Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.
Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.
